Research Topics
| Ms FreedmanSummaryAffiliation: University of Ottawa Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Cerebrospinal fluid analysis in the diagnosis of multiple sclerosisEdward J Thompson
Department of Neuroimmunology, National Hospital for Neurology and Neurosurgery, Queen Square, London, Ontario, Canada
Adv Neurol 98:147-60. 2006- MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndromeJessica M Nielsen
MS Center, Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
BMC Neurol 9:19. 2009..Here we assess the predictive value of clinically defined dissemination in space at first presentation for time to clinically definite MS (CDMS)... - Improving long-term follow-up studies of immunomodulatory therapiesMark S Freedman
University of Ottawa, Ottawa, Ontario, Canada
Neurology 76:S35-8. 2011..With careful consideration of LTFU limitations and study design, it is possible to attain a high degree of rigor in future studies... - Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statementMark S Freedman
Department of Medicine Neurology, University of Ottawa, Multiple Sclerosis Research Clinic, The Ottawa Hospital, Ottawa, Ontario, Canada
Arch Neurol 62:865-70. 2005..These recommendations for establishing a standard for the evaluation of CSF in patients suspected of having MS should greatly complement the new criteria in ensuring that a correct diagnosis of MS is being made... - Bone marrow transplantation: does it stop MS progression?Mark S Freedman
University of Ottawa, The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
J Neurol Sci 259:85-9. 2007..The rationale and methodology are discussed along with recommendations for patient selection. Results of several small studies are presented along with some preliminary results from the ongoing Canadian effort... - Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS studyM S Freedman
Ottawa Hospital General Campus, Ottawa, Ontario, Canada
Mult Scler 11:41-5. 2005..Objective: An OWIMS extension permitted assessment of longer-term efficacy/safety of qw IFN beta-1a in relapsing-remitting multiple sclerosis (RRMS)... - Immunoablative therapy as a treatment aggressive multiple sclerosisHarold Atkins
Ottawa Hospital Blood and Marrow Transplant Program, General Campus, University of Ottawa, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada
Neurol Clin 23:273-300, ix. 2005 - Primary progressive multiple sclerosis: cerebrospinal fluid considerationsMark S Freedman
Department of Medicine Neurology, University of Ottawa, Ottawa Hospital General Campus, 501 Smith Road, Box 601, Ottawa, Ontario K1H 8L6, Canada
Mult Scler 10:S31-4; discussion S34-5. 2004..Here we explore what the CSF can tell about an individual's disease process and outline the current state of the art in terms of CSF analysis. Used properly, the CSF can be very helpful in clarifying a diagnosis of PPMS... - Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparisonMark S Freedman
Department of Medicine Neurology, University of Ottawa, Ottawa, Ontario, Canada
Eur Neurol 60:1-11. 2008..In the absence of head-to-head studies for all products used to treat RRMS, it still may be possible to compare treatment effects by applying evidence-based medicine principles... - Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS studyM S Freedman
Department of Medicine Neurology, University of Ottawa, Ottawa, Ontario, Canada
Mult Scler 14:1234-41. 2008.... - Induction vs. escalation of therapy for relapsing multiple sclerosis: the evidenceMark S Freedman
Multiple Sclerosis Research Unit, The Ottawa Hospital General Campus, University of Ottawa, Ottawa, Canada
Neurol Sci 29:S250-2. 2008..This paper discusses the rationale for either regimen... - Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological eventM S Freedman
University of Ottawa, The Ottawa Hospital General Campus, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
Mult Scler 15:422-30. 2009..There is no specific serum-based biomarker for the diagnosis or prognosis of relapsing-remitting multiple sclerosis (RRMS)... - Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining commandMark S Freedman
University of Ottawa, Smyth Rd, Ottawa, ON, Canada K1H 8L6
Curr Med Res Opin 25:2459-70. 2009.... - The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study GroupMark S Freedman
University of Ottawa, Ottawa Hospital Research Institute, Ontario, Canada
Mult Scler 16:503-10. 2010..This article reviews the consensus derived from our group on the rationale for mesenchymal stem cell transplantation, the methodology for generating mesenchymal stem cells and the first treatment protocol for multiple sclerosis patients... - International consensus statement on the use of disease-modifying agents in multiple sclerosisM S Freedman
Multiple Sclerosis Research Clinic, The Ottawa Hospital, Ontario, Canada
Mult Scler 8:19-23. 2002..To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit... - Disease-modifying drugs for multiple sclerosis: current and future aspectsMark S Freedman
University of Ottawa and Ottawa Health Research Institute, Canada
Expert Opin Pharmacother 7:S1-9. 2006..Ongoing research targeting a variety of mechanisms and processes means there is much promise for the future treatment of MS... - Immunologic therapy for relapsing-remitting multiple sclerosisH J MacLean
Multiple Sclerosis Clinic, University of Ottawa, Ottawa Hospital-General Campus, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada
Curr Neurol Neurosci Rep 1:277-85. 2001..Evidence suggests that early intervention with these agents will yield the best results in the long run. The current approach to treatment of RRMS is the focus of this discussion... - Monocyte-derived cytokines in multiple sclerosisL G Filion
Department of Biochemistry, University of Ottawa, Ottawa, Ontario, Canada
Clin Exp Immunol 131:324-34. 2003..Although it is believed that inflammation tends to diminish in SPMS patients, our data show that inflammatory cytokines continue to be released at high levels, suggesting that IFN-beta or IL10 treatment may be beneficial for this group... - A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesP W O'Connor
University of Toronto, Ontario, Canada
Neurology 66:894-900. 2006..In this randomized, double-blind, placebo-controlled Phase II study, the authors examined the safety and efficacy of oral teriflunomide in multiple sclerosis (MS) with relapses... - Quantifying axonal loss after optic neuritis with optical coherence tomographyFiona Costello
Division of Neurology, Ottawa, Ontario Canada
Ann Neurol 59:963-9. 2006..To determine to what degree changes in retinal nerve fiber layer (RNFL) thickness after optic neuritis (ON) correlate with either visual recovery or impairment... - Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosisLionel G Filion
Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 8M5, Canada
Clin Immunol 106:127-38. 2003..Part of the mechanism of action of IFNbeta may be to reduce MO CD86 and CD40L expression and IL12 secretion; failure to do so might signify either a lack of response or a transition to a more progressive phase of illness... - Suppressing immunity in advancing MS: too much too late, or too late for much?Mark S Freedman
Neurology 62:168-9. 2004 - Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trialF Fazekas
Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, A 8036 Graz, Austria
Neurology 71:265-71. 2008..We therefore set out to test two different doses of a new formulation of immunoglobulin termed IGIV-C 10% for suppression of both clinical and MRI disease activity as well as safety... - A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosisJ Theodore Phillips
Multiple Sclerosis Center at Texas Neurology, Baylor University Medical Center, 6301 Gaston Avenue, Suite 400 West Tower, Dallas, TX 75214, USA
Clin Ther 26:511-21. 2004..These kinds of structural changes could lead to the formation of antibodies directed against IFNbeta. Some of these anti-IFN antibodies may neutralize the biologic activity of IFNbeta... - Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesionsJacqueline T Chen
McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada
Ann Neurol 63:254-62. 2008..To assess demyelination and remyelination in vivo in acute gadolinium (Gd)-enhancing lesions of multiple sclerosis (MS)... - Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1bChris Polman
Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
J Neurol 255:480-7. 2008..The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and > or = 2 clinically silent brain MRI lesions... - Lack of association between antimyelin antibodies and progression to multiple sclerosisJens Kuhle
Department of Research, University Hospital, Basel, Switzerland
N Engl J Med 356:371-8. 2007..An increased risk of progression to clinically definite multiple sclerosis in patients with serum antibodies against myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) has been reported... - Pain due to multiple sclerosis: analysis of the prevalence and economic burden in CanadaCharles Piwko
PharmIdeas Research and Consulting Inc, Oakville, Ontario, Canada
Pain Res Manag 12:259-65. 2007..Multiple sclerosis (MS) is a neurological disease affecting approximately 50,000 Canadians. Although studies have described overall MS costs, none have focused specifically on MS-related pain... - gamma/delta T cells in multiple sclerosis: chemokine and chemokine receptor expressionPiotr P Murzenok
Division of Neurology, Ottawa Hospital General Campus, University of Ottawa, Canada
Clin Immunol 103:309-16. 2002..Alternatively, we show that lower CCR5 expression could also reflect the result of repeated in vivo stimulation of gamma delta T cells by autoantigens... - Study of Herpesvirus saimiri immortalization of gammadelta T cells derived from peripheral blood and CSF of multiple sclerosis patientsRobert A Pon
Division of Neurology, Department of Medicine, University of Ottawa, Ottawa Hospital-General Campus, 501 Smyth Rd, K1H 8L6, Ottawa, Ont, Canada
J Neuroimmunol 139:119-32. 2003..These results indicate that HVS transformation of gammadelta T cells can be used to generate lines and clones from both the CSF and PB compartments for further study and elucidation of their potential role in MS pathogenesis... - Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardizationBernard M J Uitdehaag
Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands
Mult Scler 11:227-31. 2005..This paper describes these inconsistencies and their sources, and recommends a systematic approach that attempts to reduce the variability in interpreting clinical findings... - Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLudwig Kappos
Neurology and Department of Research, University Hospital, Basel, Switzerland
Lancet 370:389-97. 2007..Our aim was to determine whether early initiation of treatment with interferon beta prevents development of confirmed disability in MS... - Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year resultsFrederik Barkhof
Department of Diagnostic Radiology and Image Analysis Center, Vrije Universiteit Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Arch Neurol 64:1292-8. 2007.... - CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosisZhihong Chen
Department of Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada
Clin Immunol 128:219-27. 2008..In addition, this new FC(3)A method we developed could readily be adapted to study other types of immune cells suspected of ADCC-type killing... - Treatment optimization in multiple sclerosisMark S Freedman
MS Research Clinic, University of Ottawa, Ottawa Hospital General Campus, Ottawa, Ontario, Canada
Can J Neurol Sci 31:157-68. 2004..Other possible causes of suboptimal treatment responses or treatment failure are also considered... - Neutralizing antibodies to biological therapies: A "touch of gray" vs a "black and white" storyMark S Freedman
Neurology 69:1386-7. 2007 - Correlation of specialized CD16(+) gammadelta T cells with disease course and severity in multiple sclerosisZhihong Chen
Department of Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada Ottawa Health Research Institute, Ottawa, ON, Canada
J Neuroimmunol 194:147-52. 2008..Understanding more about these cells and their particular function in progressive vs. non-progressive disease could provide important clues to the mechanism of immune-mediated MS disease progression... - Reaction time: An alternative method for assessing the effects of multiple sclerosis on information processing speedLindsay I Reicker
Psychology Department, Carleton University, 1125 Colonel By Drive, Ottawa, Ontario, Canada
Arch Clin Neuropsychol 22:655-64. 2007....